Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, April 28, 2015, 56 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $625.00 to $2,071,840.58.

Highlighted Stocks Traded by Insiders:

Astec Industries (ASTE) - FREE Research Report

Brock Benjamin G, who is Chief Executive Officer at Astec Industries, sold 30,000 shares at $43.39 on April 28, 2015. Following this transaction, the Chief Executive Officer owned 174,919 shares meaning that the stake was reduced by 14.64% with the 30,000-share transaction.

The shares most recently traded at $43.44, up $0.05, or 0.11% since the insider transaction. Historical insider transactions for Astec Industries go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 404
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 404
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 404

The average volume for Astec Industries has been 106,600 shares per day over the past 30 days. Astec Industries has a market cap of $987.6 million and is part of the industrial goods sector and industrial industry. Shares are up 9.54% year-to-date as of the close of trading on Tuesday.

Astec Industries, Inc. manufactures and sells equipment and components primarily for the road building, aggregate processing, geothermal, water, oil and gas, and wood processing industries in the United States and internationally. The stock currently has a dividend yield of 0.93%. The company has a P/E ratio of 24.9. Currently, there are 2 analysts who rate Astec Industries a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ASTE - FREE

TheStreet Quant Ratings rates Astec Industries as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, growth in earnings per share and notable return on equity. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Astec Industries Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Finish Line (FINL) - FREE Research Report

Lyon Glenn S, who is CEO, Chairman of the Board at Finish Line, sold 15,000 shares at $26.00 on April 28, 2015. Following this transaction, the CEO, Chairman of the Board owned 17,426 shares meaning that the stake was reduced by 46.26% with the 15,000-share transaction.

The shares most recently traded at $24.78, down $1.22, or 4.92% since the insider transaction. Historical insider transactions for Finish Line go as follows:

  • 4-Week # shares sold: 6,282
  • 12-Week # shares sold: 6,282
  • 24-Week # shares sold: 11,282

The average volume for Finish Line has been 768,700 shares per day over the past 30 days. Finish Line has a market cap of $1.2 billion and is part of the services sector and specialty retail industry. Shares are up 3.74% year-to-date as of the close of trading on Tuesday.

The Finish Line, Inc., together with its subsidiaries, operates as a specialty retailer of athletic shoes, apparel, and accessories in the United States. It operates Finish Line stores that offer performance and athletic shoes, as well as apparel and accessories for men, women, and kids. The stock currently has a dividend yield of 1.43%. The company has a P/E ratio of 15.1. Currently, there are 4 analysts who rate Finish Line a buy, 1 analyst rates it a sell, and 13 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FINL - FREE

TheStreet Quant Ratings rates Finish Line as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Finish Line Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Stemline Therapeutics (STML) - FREE Research Report

Rowinsky Eric K, who is Chief Medical Officer at Stemline Therapeutics, sold 10,824 shares at $15.77 on April 28, 2015. Following this transaction, the Chief Medical Officer owned 143,688 shares meaning that the stake was reduced by 7.01% with the 10,824-share transaction.

The shares most recently traded at $15.19, down $0.58, or 3.82% since the insider transaction. Historical insider transactions for Stemline Therapeutics go as follows:

  • 4-Week # shares bought: 2,000
  • 4-Week # shares sold: 6,413
  • 12-Week # shares bought: 2,000
  • 12-Week # shares sold: 6,413
  • 24-Week # shares bought: 2,000
  • 24-Week # shares sold: 21,698

The average volume for Stemline Therapeutics has been 120,500 shares per day over the past 30 days. Stemline Therapeutics has a market cap of $276.0 million and is part of the health care sector and drugs industry. Shares are down 9.2% year-to-date as of the close of trading on Tuesday.

Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary therapeutics for cancer stem cells and bulk tumors in the United States. Currently, there are 6 analysts who rate Stemline Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on STML - FREE

TheStreet Quant Ratings rates Stemline Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and weak operating cash flow. Get the full Stemline Therapeutics Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null